Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer
      QxMD      Google Scholar   
Citation:
J Clin Oncol vol 38 (35) 4184-93
Year:
2020
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
Yes
SDC:
No
Book Volume:
10
Parents:
2540   2758   2759   3072   3126  
Children:
None
Program:
OGC
Primary Committee:
Breast
Sec. Committees:
   
Pharmas:
GlaxoSmithKline  
Grants:
U10CA180821, U10CA180882, U24CA196171, R01CA229409, UG1CA233160, UG1CA233180, UG1CA233290, UG1CA233329, UG1CA233333, UG1CA233373, P50-CA58223, U10CA180888, UG1CA233160 (SWOG)  
Corr. Author:
 
Authors:
                                       
Networks:
LAPS-CT018, LAPS-IL057, LAPS-MA036, LAPS-NC007, LAPS-NY016, LAPS-UT003   
Study
CALGB-40601
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords: